NCT05622669 2024-04-05
FATIGUE
University of Aberdeen
Unknown
Clinical Trials
317 trialsNCT05646758 2024-03-18
A Clinical Trial of TQB2934 for Injection in Multiple Myeloma Subjects
Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
Phase 1 Unknown
NCT05346198 2024-02-23
Evaluate CART-BCMA in Patients With Relapsed and/or Refractory Multiple Myeloma
Shanghai Simnova Biotechnology Co.,Ltd.
Phase 1 Unknown
NCT01754402 2024-02-20
Bendamustine + Pomalidomide + Dex in R/R Multiple Myeloma
Duke University
Phase 1/2 Unknown
NCT06186167 2024-02-20
Amyloidosis Incidence in High-Risk Cardiac Device Patients
Midwest Heart & Vascular Specialists
Unknown
NCT06258096 2024-02-14
LI-TASTE
Academic Centre for Dentistry in Amsterdam
Phase NA Unknown
NCT05840107 2024-02-13
Study of FasT CAR-T GC012F Injection NDMM Patients
Shanghai Changzheng Hospital
Phase EARLY_PHASE1 Unknown
NCT06224309 2024-02-09
Preliminary Assessment of [18F]BL40 in PET/CT Scans
British Columbia Cancer Agency
Unknown
NCT05478993 2024-01-31
SPODUMENE
Peking University People's Hospital
Phase 2 Unknown
NCT06205823 2024-01-16
CAREMM-2305
Seoul St. Mary's Hospital
Unknown
NCT05308875 2024-01-05
Efficacy and Safety Evaluation of PD1-BCMA-CART
Bioray Laboratories
Phase NA Unknown
NCT04714827 2023-12-29
Targeting CD19 and BCMA CAR-T Cells Immunotherapy in Patients With Relapsed or Refractory Multiple Myeloma
Shanxi Province Cancer Hospital
Phase 1/2 Unknown
NCT04727008 2023-12-12
CXCR4 Modified Anti-BCMA CAR T Cells for Multiple Myeloma
Sichuan University
Phase 1 Unknown
NCT04877275 2023-12-06
ATG-010(Selinexor) in Combination With Chemotherapy in RRMM
Union Hospital, Tongji Medical College, Huazhong University of Science and Technology
Phase 2 Unknown
NCT04663100 2023-12-04
Oral Adherence in Hematological Oncology Agents and Impact on Comorbid Therapy Adherence
University of Tennessee
Phase NA Unknown
NCT06126237 2023-11-13
A Study of CM313 in Subjects With Relapsed or Refractory Multiple Myeloma
Keymed Biosciences Co.Ltd
Phase 1/2 Unknown
NCT06116734 2023-11-03
Lapelga vs Gastrofil
London Health Sciences Centre Research Institute OR Lawson Research Institute of St. Joseph's
Phase 3 Unknown
NCT04519476 2023-10-31
Selinexor Treatment for Multiple Myeloma Patients Who Are Refractory to Lenalidomide-containing Therapy.
Oncotherapeutics
Phase 1 Unknown
NCT04942067 2023-10-25
APG-2575 in Combination With Novel Therapeutic Regimens in Subjects With Relapsed or Refractory Multiple Myeloma
Ascentage Pharma Group Inc.
Phase 1/2 Unknown
NCT06067581 2023-10-05
the Safety and Efficacy of SENL103 Autologous T Cell Injection
Hebei Senlang Biotechnology Inc., Ltd.
Phase EARLY_PHASE1 Unknown
NCT05378971 2023-10-04
Clinical Research of Pomalidomide Maintenance Therapy for Primary Multiple Myeloma
LanZhou University
Phase NA Unknown
NCT04888741 2023-09-28
MoTD
University of Birmingham
Phase 2 Unknown
NCT04504526 2023-09-15
Value of Chemokine Receptor CXCR4 Imaging for Diagnosis and Prognostic Evaluation in Lymphoproliferative Diseases
First Affiliated Hospital of Fujian Medical University
Phase EARLY_PHASE1 Unknown
NCT03759093 2023-09-06
CURATE.AI Optimized Modulation for Multiple Myeloma
National University Hospital, Singapore
Phase 2/3 Unknown
NCT05174338 2023-09-06
CARS
Cedars-Sinai Medical Center
Unknown
NCT04309981 2023-08-28
Clinical Trial Using Humanized CART Directed Against BCMA (ARI0002h) in Patients With Relapsed/Refractory Multiple Myeloma to Proteasome Inhibitors, Immunomodulators and Anti-CD38 Antibody.
Institut d'Investigacions Biomèdiques August Pi i Sunyer
Phase 1/2 Unknown
NCT06007989 2023-08-23
CHIME
The Christie NHS Foundation Trust
Unknown
NCT05995808 2023-08-16
Cyclin D1 as a Prognostic Factor in Multiple Myeloma and Its Association With the Immunological Prognostic Factor PDL1 and Clinical and Biochemical Lab Tests
Sohag University
Phase NA Unknown
NCT04211259 2023-08-07
Loratadine for the Reduction of G-CSF Induced Bone Pain in Patients With Multiple Myeloma Undergoing Stem Cell Mobilization
Rutgers, The State University of New Jersey
Phase EARLY_PHASE1 Unknown
NCT05964270 2023-07-27
ITUMM
Isala
Phase NA Unknown
NCT05951816 2023-07-19
A Phase 1 Study of 99mTc-p5+14 in Healthy Volunteers and Patients With AL or ATTR Systemic Amyloidosis
University of Tennessee Graduate School of Medicine
Phase 1 Unknown
NCT04143932 2023-07-18
THD-MM-Reg
Turkish Hematology Association
Unknown
NCT04836871 2023-07-13
Double Filtration Plasmapheresis Combined With Chemotherapy
Zhongnan Hospital
Phase 1 Unknown
NCT03695744 2023-07-10
Daratumumab in Combination With Bortezomib and Dexamethasone in Newly Diagnosed Transplant Ineligible Multiple Myeloma
Singapore General Hospital
Phase 2 Unknown
NCT04814615 2023-06-27
A Diagnostic Study of CD38-Targeted ImmunoPET of Myeloma
Hoag Memorial Hospital Presbyterian
Phase 2 Unknown
NCT05920876 2023-06-27
A Study of QLS32015 in Patients With Recurrent or Refractory Multiple Myeloma
Qilu Pharmaceutical Co., Ltd.
Phase 1 Unknown
NCT03809780 2023-06-22
LENDER
Kosin University Gospel Hospital
Phase 2 Unknown
NCT03641456 2023-06-18
VRD as Induction Followed by VR Maintenance in Patients With Newly Diagnosed High Risk Multiple Myeloma
Sun Yat-sen University
Phase 2 Unknown
NCT03090659 2023-06-12
LEGEND-2
Nanjing Legend Biotech Co.
Phase 1/2 Unknown
NCT05855122 2023-06-02
Safety and ASCT-related Symptom Burden Optimization of Tocilizumab in ASCT Following HD Melphalan Conditioning for Multiple Myeloma Patients
The First Affiliated Hospital of Soochow University
Phase 4 Unknown
NCT05271682 2023-05-16
A Study Evaluating Safety, Tolerability and Clinical Activity of FHND6091 in Patients With Multiple Myeloma
Jiangsu Chia Tai Fenghai Pharmaceutical Co., Ltd.
Phase 1 Unknown
NCT05857982 2023-05-15
Mitoxantrone Hydrochloride Liposome Injection in the Treatment of Relapsed/Refractory Multiple Myeloma
Second Affiliated Hospital of Soochow University
Phase 1/2 Unknown
NCT05858203 2023-05-15
AATF/Che-1
Regina Elena Cancer Institute
Unknown
NCT01685814 2023-04-27
Lenalidomide, Adriamycin, Dexamethasone (RAD) Versus Lenalidomide, Bortezomib, Dexamethasone (VRD) for Induction in Newly Diagnosed Multiple Myeloma Followed by Response-adapted Consolidation and Lenalidomide Maintenance
Wuerzburg University Hospital
Phase 3 Unknown
NCT05749133 2023-04-20
Safety and Efficacy of Anti-GPRC5D CAR-T Cells Therapy in the Treatment of r/r MM
Institute of Hematology & Blood Diseases Hospital, China
Phase 1/2 Unknown
NCT04272151 2023-04-18
Safety and Efficacy of BCMA-Targeted CAR-T Therapy for Relapsed/Refractory Multiple Myeloma
Chongqing Precision Biotech Co., Ltd
Phase 1/2 Unknown
NCT04861480 2023-04-18
Dual-target CAR-T Cells (C-4-29) in the Treatment of Relapsed/Refractory Multiple Myeloma
Chongqing Precision Biotech Co., Ltd
Phase 1 Unknown
NCT05438394 2023-04-14
Clinical Study of Safety and Tolerability of Melphalan Hydrochloride for R/R MM
Peking University People's Hospital
Phase 1 Unknown
NCT05802992 2023-04-07
The Efficacy and Safety of Colchicine Combined With Conventional Therapy in Multiple Myeloma Patients
Affiliated Hospital of Nantong University
Phase 3 Unknown
NCT02931942 2023-03-16
Changing Over Time of Ascorbic Acid After Chemotherapy
Maastricht University Medical Center
Unknown